Ignite Creation Date:
2024-05-06 @ 2:40 PM
Last Modification Date:
2024-10-26 @ 1:35 PM
Study NCT ID:
NCT04390126
Status:
UNKNOWN
Last Update Posted:
2021-01-20
First Post:
2020-05-14
Brief Title:
COVID-19 Related Lockdown Effects On Chronic Diseases
Sponsor:
Centre Hospitalier Universitaire Dijon
Organization:
Centre Hospitalier Universitaire Dijon
Study Overview
Official Title:
COVID-19 Related Lockdown Effects On Chronic Diseases
Status:
UNKNOWN
Status Verified Date:
2020-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLEO-CD
Brief Summary:
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation Our hypothesis is that in patients with chronic diseases confinement leads to changes in health behaviours adherence to pharmacological treatment lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short medium and long term
Some messages about the additional riskdanger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17 2020 the date on which containment began in France This is the case for example for corticosteroids non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors ACE inhibitors and angiotensin II receptor antagonists ARBs2 These four major classes of drugs are widely prescribed in patients with chronic diseases diseases specifically selected in our study corticosteroids haematological malignancies multiple sclerosis Hortons disease ACE inhibitorsARAs2 heart failure chronic coronary artery disease Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug Discontinuation of this antiplatelet agent which must be taken for life after an infarction exposes the patient to a major risk of a new cardiovascular event
The current difficulty of access to care due to travel restrictions a theoretical limit in the context of French confinement but a priori very real the impossibility of consulting overloaded doctors or the cancellation of medical appointments medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring
Eight Burgundian cohorts of patients with chronic diseases chronic coronary artery disease heart failure multiple sclerosis Hortons disease AMD haemopathic malignancy chronic respiratory failure idiopathic fibrosis PAH haemophilia cohort will study the health impact of the containment related to the COVID-19 pandemic
Some messages about the additional riskdanger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17 2020 the date on which containment began in France This is the case for example for corticosteroids non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors ACE inhibitors and angiotensin II receptor antagonists ARBs2 These four major classes of drugs are widely prescribed in patients with chronic diseases diseases specifically selected in our study corticosteroids haematological malignancies multiple sclerosis Hortons disease ACE inhibitorsARAs2 heart failure chronic coronary artery disease Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug Discontinuation of this antiplatelet agent which must be taken for life after an infarction exposes the patient to a major risk of a new cardiovascular event
The current difficulty of access to care due to travel restrictions a theoretical limit in the context of French confinement but a priori very real the impossibility of consulting overloaded doctors or the cancellation of medical appointments medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring
Eight Burgundian cohorts of patients with chronic diseases chronic coronary artery disease heart failure multiple sclerosis Hortons disease AMD haemopathic malignancy chronic respiratory failure idiopathic fibrosis PAH haemophilia cohort will study the health impact of the containment related to the COVID-19 pandemic
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None